Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Monday

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) will likely be announcing its Q3 2026 resultson Monday, November 9th. Analysts expect the company to post earnings of ($0.60) per share and revenue of $1.25 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.06). On average, analysts expect Olema Pharmaceuticals to post ($2.43) EPS for the current fiscal year and ($2.72) EPS for the next fiscal year.

Olema Pharmaceuticals Stock Up 8.4%

Shares of OLMA opened at $7.33 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.86 and a current ratio of 8.86. The company has a 50-day simple moving average of $8.49 and a 200-day simple moving average of $13.65. Olema Pharmaceuticals has a 52 week low of $6.24 and a 52 week high of $36.26. The firm has a market capitalization of $641.38 million, a P/E ratio of -3.46 and a beta of 2.12.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on OLMA shares. JPMorgan Chase & Co. decreased their target price on Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, August 13th. Weiss Ratings raised Olema Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 21st. Stifel Nicolaus cut their price target on Olema Pharmaceuticals from $48.00 to $30.00 and set a “buy” rating for the company in a report on Monday, September 14th. Wall Street Zen downgraded Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Finally, HC Wainwright decreased their price objective on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $40.60.

View Our Latest Report on Olema Pharmaceuticals

About Olema Pharmaceuticals

(Get Free Report)

Olema Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with an emphasis on hormone receptor-positive breast cancer. The company’s research is centered on treatments designed to address cancer biology and resistance mechanisms that can limit the effectiveness of existing endocrine therapies.

Olema’s lead product candidate is palazestrant, an oral selective estrogen receptor degrader (SERD) being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Featured Stories

Earnings History for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.